Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model-Reference-Cited by-同舟云学术

Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model

Published:2017-11 Issue: Volume:814 Page:161-168
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Ando Shiori,Funato Michinori,Ohuchi Kazuki,Kameyama Tsubasa,Inagaki Satoshi,Seki Junko,Kawase Chizuru,Tsuruma Kazuhiro,Shimazawa Masamitsu,Kaneko Hideo,Hara Hideaki

Funder

Ministry of Health, Labor and Welfare

Publisher

Elsevier BV

Subject

Pharmacology

Reference31 articles.

1. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy;Acsadi;J. Neurosci. Res.,2009

2. Oxidative stress and Parkinson's disease;Blesa;Front. Neuroanat.,2015

3. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy;Brichta;Hum. Mol. Genet.,2003

4. The survival motor neuron protein in spinal muscular atrophy;Coovert;Hum. Mol. Genet.,1997

5. The neurobiology of childhood spinal muscular atrophy;Crawford;Neurobiol. Dis.,1996

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Modeling as a Tool for Testing Therapeutics for Spinal Muscular Atrophy and IGHMBP2-Related Disorders;Biology;2023-06-16

2. Pathophysiology and Management of Fatigue in Neuromuscular Diseases;International Journal of Molecular Sciences;2023-03-05

3. Mitochondrial Dysfunction in Spinal Muscular Atrophy;International Journal of Molecular Sciences;2022-09-17

4. Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy;Biology;2022-06-10

5. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine;Cell Reports Medicine;2021-07